ArticleScience immunology2020
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
Abstract read
In one paragraph
Article in Science immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed.
- Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.The Journal of experimental medicine · 2024Trial
- Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026Review
- TLR ligands as immunomodulators: mechanistic insights and therapeutic potential in infectious and inflammatory diseases.Molecular biology reports · 2026Review
- Myeloid compartment reprogramming through nanoparticle-delivered resiquimod blocks paracrine growth support and activates phagocytosis to slow tumor progression in endogenous mouse medulloblastoma and diffuse midline glioma models.bioRxiv : the preprint server for biology · 2026Article
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- Recent Advances, Bottlenecks, and Future Directions inVaccines · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TB.Frontiers in immunology · 2026Article
- TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.Frontiers in immunology · 2026Article
- 3M-052 combined inhibitory anti-TNFR2 synergistically suppresses colon cancer progression.Frontiers in immunology · 2026Article
- Unveiling an Immunological Mystery: Deciphering the Durability Divide in Vaccine-Elicited Antibody Responses.Current HIV research · 2026Review
- ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates.NPJ vaccines · 2025Article
- In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8Journal for immunotherapy of cancer · 2025Article
- Advances in vaccine adjuvant development and future perspectives.Drug delivery · 2025Review
- Review
- Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.Nature immunology · 2025Article
- KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Progress and Recent Developments in HIV Vaccine Research.Vaccines · 2025Review
- Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.PLoS pathogens · 2025Article
- Sustained Vaccine Exposure Elicits More Rapid, Consistent, and Broad Humoral Immune Responses to Multivalent Influenza Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Sudhir Pai KasturiEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0002-6421-2040
Mohammed Ata Ur RasheedEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0002-8819-3112
Colin Havenar-DaughtonDivision of Vaccine Discovery, La Jolla Institute of Immunology, La Jolla, CA, USA.ORCID 0000-0002-2880-3927
Mathew PhamEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0002-4788-9658
Traci LegereEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0001-6393-719X
Zarpheen Jinnah SherEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.
Yevgeny KovalenkovEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0003-2396-7962
Sanjeev GumberEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0001-9048-2717
Jessica Y HuangEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0001-8674-5924
Raphael GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-3867-0232
William FulpVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Alicia SatoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-8371-8007
Sheetal SawantDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0002-1109-7907
Sherry Stanfield-OakleyDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0002-6347-1956
Nicole YatesDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0003-2678-1311
Celia LaBrancheDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0002-6653-6655
S Munir AlamDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0003-0941-0703
Georgia TomarasDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Guido FerrariDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
David MontefioriDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.ORCID 0000-0003-0856-6319
Jens WrammertEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0002-1733-4424
Francois VillingerEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA.ORCID 0000-0002-7790-2008
Mark Tomai3M Drug Delivery Systems, St. Paul, MN, USA.ORCID 0000-0002-6362-9151
John Vasilakos3M Drug Delivery Systems, St. Paul, MN, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, USA.ORCID 0000-0002-4644-2619
Steven G ReedInfectious Disease Research Institute, Seattle, WA, USA.
Barton F HaynesDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham, NC, USA.
Shane CrottyDivision of Vaccine Discovery, La Jolla Institute of Immunology, La Jolla, CA, USA.ORCID 0000-0002-6484-6262
Rafi AhmedEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA. bpulend@stanford.edu rahmed@emory.edu.ORCID 0000-0002-9591-2621
Bali PulendranEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, 954, Gatewood Road, Atlanta, GA, USA. bpulend@stanford.edu rahmed@emory.edu.ORCID 0000-0001-6517-4333
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MYNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2017 to 2026
$40.7MTargeting mTOR to Enhance Immunogenicity and Efficacy of HIV VaccinesP01AI088575 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2010 to 2013
$11.4MMaximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3MModulating durability of HIV-1 env specific humoral immunity with a novel TLR7/8 targeted formulationK01OD023039 · OD · EMORY UNIVERSITY · PI KASTURI, SUDHIR PAI · 2016 to 2018
$1.0MNCRR NIH HHS P51 RR000165NIAID NIH HHS P01 AI088575NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI125068NIH HHS K01 OD023039NIH HHS P51 OD011132
Abstract
A fundamental challenge in vaccinology is learning how to induce durable antibody responses. Live viral vaccines induce antibody responses that last a lifetime, but those induced with subunit vaccines wane rapidly. Studies in mice and humans have established that long-lived plasma cells (LLPCs) in the bone marrow (BM) are critical mediators of durable antibody responses. Here, we present data that adjuvanting an HIV-1 clade C 1086.C-derived gp140 immunogen (Env) with a novel synthetic Toll-like receptor (TLR)-7/8 agonist named 3M-052 formulated in poly(lactic-
Indexed as
Adjuvants, ImmunologicAnimalsenv Gene Products, Human Immunodeficiency VirusFemaleHeterocyclic Compounds, 3-RingImmunity, HumoralMacaca mulattaMaleMembrane GlycoproteinsPlasma CellsStearic AcidsToll-Like Receptor 7Toll-Like Receptor 8Adjuvants, Immunologicenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1Heterocyclic Compounds, 3-RingMEDI9197Membrane GlycoproteinsStearic AcidsTlr7 protein, mouseTLR8 protein, mouseToll-Like Receptor 7Toll-Like Receptor 8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.